Masahiro Kagabu

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy

Andrea Facciabene, Francesco De Sanctis, Stefano Pierini et al. · OncoImmunology · 2017 · 70 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations

Kosei Hasegawa, Masahiro Kagabu, Mika Mizuno et al. · Investigational New Drugs · 2017 · 34 citations

Medicine, Oncology, Pharmacology +15

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix

Tadahiro Shoji, Eriko Takatori, Tatsunori Saito et al. · Cancer Chemotherapy and Pharmacology · 2012 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass

Tadahiro Shoji, Eriko Takatori, Yoko Furutake et al. · International Journal of Clinical Oncology · 2016 · 23 citations · Full text

Medicine, Oncology, Surgery +12

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

Rebecca C. Arend, Bradley J. Monk, Ronnie Shapira‐Frommer et al. · Journal of Clinical Oncology · 2023 · 23 citations · Full text

Medicine, Oncology, Pharmacology +15